StockNews.com Begins Coverage on ChromaDex (NASDAQ:CDXC)

StockNews.com began coverage on shares of ChromaDex (NASDAQ:CDXC – Get Rating) in a report published on Thursday morning. The firm issued a buy rating on the stock.

Separately, HC Wainwright cut their price objective on ChromaDex from $5.50 to $5.00 and set a buy rating for the company in a report on Monday, March 13th.

ChromaDex Stock Down 3.1 %

Shares of CDXC opened at $1.58 on Thursday. ChromaDex has a one year low of $1.15 and a one year high of $2.99. The business has a fifty day moving average of $1.83 and a 200 day moving average of $1.64.

ChromaDex (NASDAQ:CDXC – Get Rating) last issued its quarterly earnings data on Wednesday, March 8th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.01. ChromaDex had a negative return on equity of 77.39% and a negative net margin of 22.96%. The company had revenue of $21.00 million during the quarter, compared to analyst estimates of $21.08 million. During the same quarter in the previous year, the company posted ($0.08) earnings per share. On average, research analysts predict that ChromaDex will post -0.14 EPS for the current year.

Institutional Trading of ChromaDex

Several hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its holdings in ChromaDex by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 558,849 shares of the company’s stock valued at $938,000 after purchasing an additional 5,524 shares during the period. Cambridge Investment Research Advisors Inc. grew its holdings in ChromaDex by 5.9% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 126,558 shares of the company’s stock valued at $213,000 after purchasing an additional 7,000 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in ChromaDex by 74.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 39,300 shares of the company’s stock valued at $66,000 after purchasing an additional 16,800 shares during the period. International Assets Investment Management LLC bought a new stake in ChromaDex during the fourth quarter valued at about $34,000. Finally, Oppenheimer & Co. Inc. grew its holdings in ChromaDex by 127.3% during the second quarter. Oppenheimer & Co. Inc. now owns 39,110 shares of the company’s stock valued at $65,000 after purchasing an additional 21,900 shares during the period. Institutional investors own 42.81% of the company’s stock.

About ChromaDex

(Get Rating)

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.